SCHEMBL4057475

SCHEMBL4057475

CCn1nc(-c2cccnc2)ccc1=O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TBXAS1 P24557 1/20 0.55
CYP2A6 P11509 5/20 0.51
CYP3A4 P08684 3/20 0.51
CYP2E1 P05181 2/20 0.51
CYP2C9 P11712 2/20 0.51
CYP2B6 P20813 2/20 0.51
CYP2C19 P33261 2/20 0.51
HDAC1 Q13547 1/20 0.47
TSHR P16473 1/20 0.47
HTT P42858 1/20 0.47
MET P08581 3/20 0.47
KDM4E B2RXH2 1/20 0.44
IRAK4 Q9NWZ3 2/20 0.44
TNF P01375 1/20 0.44
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
FYN P06241 1/20 0.43
ALDH1A1 P00352 1/20 0.42
CYP1A2 P05177 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15317759 0.84 HDAC1 (0.45) TBXAS1CYP2A6CYP3A4CYP2E1CYP2C9
SCHEMBL4054492 0.83 HTT (0.62) TSHRHTTKDM4EMEN1KMT2A
Bromide SCHEMBL5751833 0.82 HTT (0.61) TSHRHTTKDM4EMEN1KMT2A
SCHEMBL4061176 0.82 MAPT (0.52) HDAC1TSHRHTTMETKDM4E
SCHEMBL23202474 0.81 MET (0.55) CYP2A6CYP2E1CYP2C9CYP2B6CYP2C19
SCHEMBL31096514 0.81 MET (0.55) CYP2A6CYP2E1CYP2C9CYP2B6CYP2C19
SCHEMBL28158481 0.81 HDAC1 (0.61) CYP2A6CYP3A4CYP2E1CYP2C9CYP2B6
SCHEMBL12744791 0.80 CYP2C9 (0.54) TBXAS1CYP2A6CYP3A4CYP2E1CYP2C9
SCHEMBL4059984 0.80 TBXAS1 (0.56) TBXAS1CYP2A6CYP3A4CYP2E1CYP2C9
SCHEMBL4050698 0.79 MEN1 (0.46) TSHRHTTMETKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2655357-B1 INDAZOLYL TRIAZOLE DERIVATIVES AS IRAK INHIBITORS MERCK SERONO SA (CH) 2016-06-22 EP disclosed
US-7511038-B2 Pyridazin-3(2H)-one derivatives and their use as PDE4 inhibitors LABORATORIOS ALMIRALL S.A. (ES) 2009-03-31 US disclosed
US-20070197536-A1 phosphodiesterase enzyme inhibitor; 4-[(3-chlorophenyl)amino]-2-ethyl-5-(1-hydroxyethyl)-6-phenylpyridazin-3(2H)-one; potent antiinflammatory agent; asthma, atopic dermatitis, psoriasis, chronic obstructive pulmonary disease, rheumatoid arthritis, irritable bowel disease LABORATORIOS ALMIRALL, S.A. (ES) 2007-08-23 US disclosed
CN-1878759-A Pyridazin-3 (2H) -one derivatives and their use as PDE4 inhibitors ALMIRALL PRODESFARMA SA (ES) 2006-12-13 CN disclosed
EP-1682519-A1 PYRIDAZIN-3(2H)-ONE DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS Almirall Prodesfarma, S.A. (ES) 2006-07-26 EP disclosed
WO-2005049581-A1 PYRIDAZIN-3 (2H) -ONE DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS ALMIRALL PRODESFARMA, S.A. (ES) 2005-06-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197536-A1 phosphodiesterase enzyme inhibitor; 4-[(3-chlorophenyl)amino]-2-ethyl-5-(1-hydroxyethyl)-6-phenylpyridazin-3(2H)-one; potent antiinflammatory agent; asthma, atopic dermatitis, psoriasis, chronic obstructive pulmonary disease, rheumatoid arthritis, irritable bowel disease PDE12, PDE4A, PDE7A TBXAS1 498/4885CYP2A6 137/4885CYP3A4 40/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.